Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma

Chen, Ting; Liu, Jinxin; Zhang, He; Li, Jiatong; Shang, Guanning

doi:10.3389/fonc.2022.907472

Cited by 18 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MALAT1: FW: GGA TCC TAG ACC AGC ATG CC; RV: AAA GGT TAC CAT AAG TAA GTT CCA GAA AA ( 31 ). The detailed method for PCR was described previously ( 32 ).…”

Section: Methodsmentioning

confidence: 99%

LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer

et al. 2022

View full text Add to dashboard Cite

Pancreatic cancer is the fourth leading cause of cancer death in the United States. The main methods of treating pancreatic cancer are surgery and chemotherapy, but the treatment efficacy is low with a poor prognosis. Immunotherapy represented by PD-1/PD-L1 has brought a milestone progress in the treatment of pancreatic cancer. However, the unique tumor microenvironment of pancreatic cancer presents challenges for immunotherapy. In addition, m6A is a common RNA modification and a potential molecular target in tumor therapy. The expression pattern of m6A in pancreatic cancer is still unclear. LncRNAs also play an essential role in pancreatic cancer development and treatment. In this study, we found that some m6A regulators were significantly elevated in pancreatic cancer and associated with the expression of PD-1/PD-L1. Moreover, we observed that METTL3 can increase the expression of PD-L1. Notably, METTL3 positively regulates the expression of lncRNA MALAT1 in pancreatic cancer cells. Strikingly, lncRNA MALAT1 increased the expression of PD-L1 in pancreatic cancer cells. This finding indicated that METTL3 regulated the expression of PD-L1 possibly via targeting lncRNA MALAT1 in pancreatic cancer cells. Lastly, MALAT1 governed the viability of pancreatic cancer cells. Taken together, lncRNA MALAT1 is involved in METTL3-mediated promotion of PD-L1 expression in pancreatic cancer.

show abstract

“…MALAT1: FW: GGA TCC TAG ACC AGC ATG CC; RV: AAA GGT TAC CAT AAG TAA GTT CCA GAA AA ( 31 ). The detailed method for PCR was described previously ( 32 ).…”

Section: Methodsmentioning

confidence: 99%

LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Besides these gene mutations, non-coding RNAs have been reported to involve in regulating TME and immunotherapy in lung cancer. Non-coding RNAs have been reported to involved in human cancer development and progression ( Ghafouri-Fard et al, 2020 ; Yan and Bu, 2021 ; Chen T. et al, 2022 ; Liu and Shang, 2022 ). Evidence has shown that lncRNAs play an essential role in NSCLC initiation, development and progression ( Osielska and Jagodzinski, 2018 ; Wang et al, 2018 ; Hu et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Wang

Zhu²,

Yang³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.

show abstract

“…It has been known that microRNA (miRNA) has approximately 22 nucleotides and targets gene expression via regulation of post-transcription (19,20). Now, noncoding RNAs have been validated to critically participate in oncogenesis in various types of cancers (21)(22)(23)(24)(25). Not surprisingly, noncoding RNAs regulated numerous cellular biological processes and dysregulated noncoding RNAs lead to various diseases, including cancer (26)(27)(28)(29).…”

Section: Introductionmentioning

confidence: 99%

The functions of long noncoding RNAs on regulation of F-box proteins in tumorigenesis and progression

et al. 2022

View full text Add to dashboard Cite

Accumulated evidence has revealed that F-box protein, a subunit of SCF E3 ubiquitin ligase complexes, participates in carcinogenesis and tumor progression via targeting its substrates for ubiquitination and degradation. F-box proteins could be regulated by cellular signaling pathways and noncoding RNAs in tumorigenesis. Long noncoding RNA (lncRNA), one type of noncoding RNAs, has been identified to modulate the expression of F-box proteins and contribute to oncogenesis. In this review, we summarize the role and mechanisms of multiple lncRNAs in regulating F-box proteins in tumorigenesis, including lncRNAs SLC7A11-AS1, MT1JP, TUG1, FER1L4, TTN-AS1, CASC2, MALAT1, TINCR, PCGEM1, linc01436, linc00494, GATA6-AS1, and ODIR1. Moreover, we discuss that targeting these lncRNAs could be helpful for treating cancer via modulating F-box protein expression. We hope our review can stimulate the research on exploration of molecular insight into how F-box proteins are governed in carcinogenesis. Therefore, modulation of lncRNAs is a potential therapeutic strategy for cancer therapy via regulation of F-box proteins.

show abstract

Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma

Cited by 18 publications

References 38 publications

LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer

LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

The functions of long noncoding RNAs on regulation of F-box proteins in tumorigenesis and progression

Contact Info

Product

Resources

About